Benjamin Palleiko Sells 1,038 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 1,038 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $15.00, for a total transaction of $15,570.00. Following the transaction, the chief executive officer owned 429,667 shares in the company, valued at $6,445,005. This represents a 0.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

KalVista Pharmaceuticals Stock Performance

KALV opened at $15.83 on Friday. The business has a 50 day moving average price of $15.50 and a two-hundred day moving average price of $13.88. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The company has a market capitalization of $800.14 million, a price-to-earnings ratio of -4.01 and a beta of -0.19. KalVista Pharmaceuticals, Inc. has a 1-year low of $9.23 and a 1-year high of $19.00.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on KALV. Citigroup reaffirmed a “market outperform” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. Needham & Company LLC increased their target price on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Finally, Citizens Jmp reduced their target price on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a report on Tuesday, November 11th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.40.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Invesco Ltd. raised its holdings in shares of KalVista Pharmaceuticals by 23.1% during the fourth quarter. Invesco Ltd. now owns 77,864 shares of the specialty pharmaceutical company’s stock valued at $1,258,000 after acquiring an additional 14,621 shares during the period. XTX Topco Ltd purchased a new position in KalVista Pharmaceuticals during the 4th quarter worth approximately $428,000. Vestal Point Capital LP grew its position in KalVista Pharmaceuticals by 152.0% during the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock worth $30,524,000 after purchasing an additional 1,140,000 shares in the last quarter. Virtus Investment Advisers LLC raised its stake in KalVista Pharmaceuticals by 364.9% during the 4th quarter. Virtus Investment Advisers LLC now owns 40,414 shares of the specialty pharmaceutical company’s stock valued at $653,000 after purchasing an additional 31,721 shares during the period. Finally, Squadron Capital Management LLC purchased a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at $11,305,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.